EDX MEDICAL GROUP PLC APPOINTS PRODUCT DEVELOPMENT DIRECTOR
EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has today announced the appointment of Claire Bevis-Mott as Director of Product Development. Mrs Bevis-Mott joins EDX Medical while the Company is accelerating the development of new diagnostic products to help meet global demand from healthcare providers.
Mrs Bevis-Mott is a proven scientific leader in the life sciences sector, working in leadership and management positions with companies including Illumina Ltd where she worked for 17 years commercialising numerous products and received an “Accomplished Inventor” award as the most prolific female inventor within the Product Development team. Previously, she held a research post with the Medical Research Council.
Claire Bevis-Mott commented: “I am excited to be joining the EDX Medical team which is clearly committed to bringing innovative diagnostic products to patients. The need for rapid diagnosis and personalised treatments across a wide range of diseases has never been greater. Having taken complex products to market, I have deep experience in all phases of the product lifecycle and am passionate about the creation and delivery of novel solutions that can make a difference to patients.”
Professor Sir Chris Evans OBE, founder of EDX Medical, commented: “We’re thrilled to welcome Claire to EDX Medical as she has demonstrated over many years, particularly with a world leader in human genomics such as Illumina, a tremendous ability to develop class-leading testing products. Claire’s proven expertise in taking projects from laboratory into marketable products fits hand in glove with our vision to deliver the most advanced diagnostic tests to patients.”
Dr Mike Hudson, CEO of EDX Medical, commented: “We are delighted that Claire is joining our international development team at a time when we are growing our portfolio of products and services. Her outstanding project management skills and understanding behind the technical delivery of complex genomic products will immediately enhance our ability to deliver ‘best-in-class’ innovative products.”
